A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT
NCT ID: NCT05125354
Last Updated: 2022-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
33 participants
OBSERVATIONAL
2022-01-06
2022-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
NCT05323253
Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)
NCT03353077
Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC
NCT05065346
Efficacy and Toxicity of SCART
NCT06341257
Alpha Radiation Emitters Device for the Treatment of of Malignant Cutaneous Tumors
NCT04068155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Evaluation of long-term outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response. These outcomes include:
* Safety - assessment of late onset of Alpha DaRT related AE in patients treated with the Alpha DaRT seeds
* Efficacy -
* assessment of local recurrence rates in patients who achieved initial complete response (CR) following the Alpha DaRT treatment
* assessment of duration of response in patients who achieved initial CR following the Alpha DaRT treatment
* assessment of survival status in patients treated with the Alpha DaRT seeds
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Available information in medical charts and records (electronic or paper)
Exclusion Criteria
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alpha Tau Medical LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noga Kurman, MD
Role: PRINCIPAL_INVESTIGATOR
Davidof Cancer Institution at Rabin Medical Center Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Davidof Cancer Institution at the Rabin Medical Center Israel
Petah Tikva, , Israel
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
Meldola, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTP-SCC-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.